CYduct Diagnostics, Inc.
CYDX · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.49 | -0.37 | -0.31 | 0.01 |
| FCF Yield | -6.41% | -11.53% | -9.93% | -16.53% |
| EV / EBITDA | -8.89 | -6.41 | -9.19 | -1.27 |
| Quality | ||||
| ROIC | 21.96% | 30.59% | 39.15% | 37.43% |
| Gross Margin | 66.99% | 69.89% | 67.53% | 71.83% |
| Cash Conversion Ratio | 0.17 | 0.42 | 0.56 | 0.30 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.02% | -3.51% | -9.47% | -21.50% |
| Free Cash Flow Growth | 34.48% | -108.91% | -120.43% | -375.02% |
| Safety | ||||
| Net Debt / EBITDA | -1.69 | -1.17 | -1.49 | -0.33 |
| Interest Coverage | -9.68 | -14.12 | -23.82 | -309.03 |
| Efficiency | ||||
| Inventory Turnover | 2.29 | 2.48 | 1.83 | 1.92 |
| Cash Conversion Cycle | -1,311.69 | -525.20 | -15,633.70 | -8,301.24 |